Rezolute，Inc.正在推进其针对肿瘤适应症的III期Uplift研究，目前患者入组工作正有条不紊地进行中。该公司预期，这项关键性临床试验的结果将在2026年年底之前揭晓。这一进展标志着Rezolute在肿瘤治疗领域迈出了坚实的一步，也为其候选药物的后续监管申请铺平了道路。随着入组工作的持续展开，业界正密切关注这一研究的最终数据，以评估其安全性与有效性。
Rezolute，Inc.正在推进其针对肿瘤适应症的III期Uplift研究，目前患者入组工作正有条不紊地进行中。该公司预期，这项关键性临床试验的结果将在2026年年底之前揭晓。这一进展标志着Rezolute在肿瘤治疗领域迈出了坚实的一步，也为其候选药物的后续监管申请铺平了道路。随着入组工作的持续展开，业界正密切关注这一研究的最终数据，以评估其安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.